Chiesi Group Completes Acquisition of KalVista Pharmaceuticals for $27.00/Share; Stock Delisted
Summary
KalVista Pharmaceuticals has been acquired by Chiesi Group for $27.00 per share, marking the completion of the tender offer and merger. The company's stock will now be delisted from Nasdaq.
Key Events
-
Acquisition Completed
Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals, Inc., making it a wholly-owned subsidiary.
-
Tender Offer Successful
Approximately 77.8% of KalVista's outstanding shares were validly tendered and accepted for payment at $27.00 per share.
-
Merger Finalized
Following the tender offer, a merger was completed, converting all remaining outstanding shares into the right to receive $27.00 per share in cash.
-
Stock Delisted
KalVista's common stock has ceased trading on the Nasdaq Global Market and will be deregistered under the Exchange Act.
Analysis
This filing confirms the definitive completion of the acquisition of KalVista Pharmaceuticals by Chiesi Group. The tender offer was successful, with 77.8% of shares tendered, and the subsequent merger means KalVista is no longer an independent public entity. This is a thesis-altering event for investors, as the company's stock will be delisted, and all shareholders will receive $27.00 per share in cash, representing a successful exit at a premium.
At the time of this filing, KALV was trading at $27.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $9.83 to $27.00. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.